Contemporary axillary surgical management in patients with pathologically node positive disease after neoadjuvant chemotherapy: a survey of members of the …
A Weiss, F Colugnati, M Mitchell, Y Li, C Marin… - Annals of surgical …, 2024 - Springer
Background Axillary lymph node dissection (ALND) is increasingly omitted for breast cancer
patients with pathologic nodal disease after neoadjuvant chemotherapy (NAC). This study …
patients with pathologic nodal disease after neoadjuvant chemotherapy (NAC). This study …
Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy
Background Neoadjuvant chemotherapy (NAC) may downstage axillary disease in node-
positive breast cancer. Several clinical trials have shown that sentinel lymph node (SLN) …
positive breast cancer. Several clinical trials have shown that sentinel lymph node (SLN) …
Surgical axillary staging before neoadjuvant chemotherapy: who gets it and why we should avoid it
K Iles, PD Strassle, CB Agala, J Button… - Annals of surgical …, 2021 - Springer
Background Surgical axillary staging demonstrating positive nodal disease before
neoadjuvant chemotherapy (NAC) necessitates axillary lymph node dissection (ALND) post …
neoadjuvant chemotherapy (NAC) necessitates axillary lymph node dissection (ALND) post …
Evaluating axillary lymph node yield after neoadjuvant chemotherapy
B Fan, K Romatoski, J Pardo, M Valero… - Annals of Surgical …, 2023 - Springer
Introduction The benefits that neoadjuvant chemotherapy (NAC) provides in treating patients
with breast cancer are well known. However, its effects on axillary lymph nodes and lymph …
with breast cancer are well known. However, its effects on axillary lymph nodes and lymph …
How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study
A Mamtani, AV Barrio, TA King, KJ Van Zee… - Annals of surgical …, 2016 - Springer
Background In breast cancer patients with nodal metastases at presentation, false-negative
rates lower than 10% have been demonstrated for sentinel node biopsy (SLNB) after …
rates lower than 10% have been demonstrated for sentinel node biopsy (SLNB) after …
Assessing the burden of nodal disease for breast cancer patients with clinically positive nodes: hope for more limited axillary surgery
S Angarita, L Ye, D Rünger, J Hadaya, JL Baker… - Annals of Surgical …, 2021 - Springer
Background Omission of axillary lymph node dissection (ALND) is accepted for patients with
one or two positive sentinel nodes, and studies are focusing on clinically node-positive …
one or two positive sentinel nodes, and studies are focusing on clinically node-positive …
Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a national cancer database (NCDB) analysis
MK Srour, J Tseng, M Luu, RF Alban… - Annals of surgical …, 2019 - Springer
Abstract Background The American College of Surgeons Oncology Group (ACOSOG) Z1071
and Sentinel Neoadjuvant (SENTINA) trials of sentinel node biopsy for node-positive breast …
and Sentinel Neoadjuvant (SENTINA) trials of sentinel node biopsy for node-positive breast …
Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy
JN Limberg, T Jones, SM Thomas, KW Ntowe… - Annals of Surgical …, 2024 - Springer
Background Axillary management after neoadjuvant chemotherapy (NAC) is evolving but
axillary lymph node dissection (ALND) remains the standard of care for patients with …
axillary lymph node dissection (ALND) remains the standard of care for patients with …
Omission of Axillary Dissection in Node Positive Breast Cancer After Neoadjuvant Systemic Therapy
GB Peery, J Pak, L Burkbauer, CB Agala… - Journal of Surgical …, 2023 - Elsevier
Introduction Guidelines recommend axillary lymph node dissection (ALND) for ypN+ positive
patients as patients receiving neoadjuvant systemic therapy (NST) were excluded from trials …
patients as patients receiving neoadjuvant systemic therapy (NST) were excluded from trials …
Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter …
C Loveland-Jones, J Gaughan, A Caudle… - European Journal of …, 2024 - Elsevier
Introduction Targeted axillary dissection (TAD) is performed after neoadjuvant systemic
therapy (NST) to decrease the rate of non-therapeutic axillary dissection (ALND) for patients …
therapy (NST) to decrease the rate of non-therapeutic axillary dissection (ALND) for patients …